Gestational Trophoblastic Disease: Prevalence, Management and Follow-Up at a Tertiary Center in Oman—An 11-Year Study

Indian Journal of Gynecologic Oncology - Tập 17 - Trang 1-4 - 2019
Fatma Al Wahaibi1, Huda Al Ghaithi2, Ruqiya AlShamsi3, Vaidyanathan Gowri4, Thuria Al Rawahi2
1Obstetrics and Gynecology Residency Training Program, Oman Medical Specialty Board, Muscat, Oman
2Obstetrics and Gynecology Department, Royal Hospital, Muscat, Oman
3Department of Histopathology, Royal Hospital, Muscat, Oman
4Obstetrics and Gynecology Department, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman

Tóm tắt

The objective of this study is to estimate the prevalence, management and follow-up of gestational trophoblastic disease (GTD) in a tertiary care center, Royal Hospital, in Oman over the last 11 years from January 2007 till December 2017. This study also looked into the reproductive outcome after trophoblastic disease treatment. This retrospective, descriptive study was carried out at Royal Hospital from Jan. 2007 to Dec. 2017. All cases with a histopathological report of hydatidiform molar disease were included. Demographic characteristics, clinical presentation physical signs, treatment and follow-up including reproductive outcome and recurrence rate were included. Two hundred and thirty-six women with GTD were included in the study. Mean maternal age was 35 years, mean gravidity 5 and parity 3. Prevalence of complete mole was 83 cases (35.1%), partial mole 144 cases (61%), choriocarcinoma (0.42%), placental site (0.42%) and invasive mole (1.27%). Thyrotoxicosis, preeclampsia and anemia were 3.8%, 7.2% and 0.8%, respectively. Mean gestational age was 10.57 ± 3.2 weeks at presentation. Persistent disease was observed in 12.3%. About 5% received chemotherapy. Metastasis was reported in 4.7% of cases, 81.8% to the lung. About 38% conceived later. This study highlights the importance of proper assessment and follow-up of histopathology diagnosis. GTD usually has a good prognosis and reproductive outcome if properly followed up and treated.

Tài liệu tham khảo

Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531–9.

Gestational trophoblastic disease, New Zealand gynaecologic cancer group guidelines, March 2018. https://www.health.govt.nz/system/files/documents/publications/gtd-guidelines-2018.pdf.

Loukovaara M, Pukkala E, Lehtovirta P, Leminen A. Epidemiology of hydatidiform mole in Finland, 1975 to 2001. Eur J Gynaecol Oncol. 2005;26(2):207–8.

Garner EI, Goldstein DP, Feltmate CM, Berkowitz RS. Gestational trophoblastic disease. Clin Obstet Gynecol. 2007;50(1):112–22.

Ahmed IAM. Gestational trophoblastic disease in Al-Thawra Hospital, Sana’a-Yemen. Yemeni J Med Sci. 2013;7.

Al Alaf SK, Ibrahim D. Prevalence and clinical observations of gestational trophoblastic diseases in maternity teaching hospital in Erbil city. WSEAS Trans. Biol. Biomed. 2010;7(3):190–9.

Javey H, Sajadi H. Hydatidiform mole in southern Iran: a statistical survey of 113 cases. Int J Gynaecol Obstet. 1978;15(5):390–5. https://doi.org/10.1002/j.1879-3479.1977.tb00716.x.

Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717–29.

Ngan HY, Kohorn EI, Cole LA, Kurman RJ, Kim SJ, Lurain JR, Seckl MJ, Sasaki S, Soper JT. Trophoblastic disease. Int J Gynaecol Obstet. 2012;119(Suppl 2):S130–6. https://doi.org/10.1016/S0020-7292(12)60026-5).

Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C, ESMO Guidelines Working Group Annals of Oncology. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):vi39–50. https://doi.org/10.1093/annonc/mdt345.

Al Riyami N, Al Riyami M, Al Hajiri T, Al Saidi S, Salman B, Kalbani M. Gestational trophoblastic disease at Sultan Qaboos University Hospital: prevalence, risk factors, histological features, sonographic findings, and outcomes. Oman Med J. 2019;34(3):200–4. https://doi.org/10.5001/omj.2019.39).

Yuk J, Baek JC, Park JE, Jo HC, Park JK, Cho IA. Incidence of gestational trophoblastic disease in South Korea: a longitudinal, population-based study. PeerJ. 2019;7:e6490. https://doi.org/10.7717/peerj.6490).

Jagtap SV, Aher V, Gadhiya S, Jagtap SS. Gestational trophoblastic disease—clinicopathological study at Tertiary Care Hospital. J Clin Diagn Res. 2017;11(8):EC27–30. https://doi.org/10.7860/JCDR/2017/27232.10458.

Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376(9742):717–29. https://doi.org/10.1016/S0140-6736(10)60280-2.

Sebire NJ, Makrydimas G, Agnantis NJ, Zagorianakou N, Rees H, Fisher RA. Updated diagnostic criteria for partial and complete hydatidiform moles in early pregnancy. Anticancer Res. 2003;23:1723–8.

Feltmate CM, Growdon WB, Wolfberg AJ, Goldstein DP, Genest DR, Chinchilla ME, Lieberman ES, Berkowitz RS. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med. 2006;51(11):902–6.

Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med. 2006;51(10):764–6.

Zhou X, Chen Y, Li Y, Duan Z. Partial hydatidiform mole progression into invasive mole with lung metastasis following in vitro fertilization. Oncol Lett. 2011;3(3):659–61. https://doi.org/10.3892/ol.2011.542.

Li X, Xu Y, Liu Y, Cheng X, Wang X, Lu W, Xie X. The management of hydatidiform mole with lung nodule: a retrospective analysis in 53 patients. J Gynecol Oncol. 2018;30(2):e16. https://doi.org/10.3802/jgo.2019.30.e16.

Thông tin
Thông tin xuất bản

Indian Journal of Gynecologic Oncology

Tập 17

1-4

Thông tin tác giả